1. Open-label, open-ended study of the safety of diclofenac sodium topical solution for management of osteoarthritis: characterization of gastrointestinal adverse events

Charles Argoff, Jeff Patrick, Zev Shainhouse

*Albany Medical College, Albany, NY, USA; Coviden, Hazelwood, MO, USA, *Consultant, Toronto, ON, Canada

2. Open-label, open-ended study of the safety of diclofenac sodium topical solution for management of osteoarthritis: characterization of application-site adverse events

Zev Shainhouse, Jeff Patrick, Charles Argoff

*Consultant, Toronto, ON, Canada; Coviden, Hazelwood, MO, USA, *Albany Medical College, Albany, NY, USA

3. Evaluation of the current practices for managing postoperative pain and characterization of patients undergoing total knee or hip arthroplasty in a real-world setting

Carmen Kirkness, Carina McLeod-Marc, Sudhir Urnik, Jason Young, Xiangyang Ye, Artis Chandram, Da-In Kim, Junyi Lin, Christopher Peters, Carl Asche

Department of Physical Therapy, College of Health, University of Utah, Salt Lake City, UT, USA, *Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA, *Department of Orthopaedics, School of Medicine, University of Utah, Salt Lake City, UT, USA, *Pfizer, Inc., New York, NY, USA, *University of Illinois College of Medicine, Peoria, ILLINOIS, USA

4. Observation of improved adherence with ongoing urine drug testing in patients with chronic pain

David Yee, Michelle Hogner, Alexander Guz, Stephanie Tew, Neenah Barkat, Rabia Ayaye, Joseph Mar, Brooke Best, Amanda Pescor

University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, USA, *Astra A. Howell Palliative Care Service, La Jolla, California, USA, *University of California Department of Pediatrics, Rady Children’s Hospital-San Diego, San Diego, California, USA, *University of California Department of Pathology and Laboratory Medicine, San Diego, California, USA

5. A novel diagnostic examination of the lumbar adhesion arachnoïditis by MRI scanning in supine and prone positions

Kenji Azuma, Masahiko Sumitani, Takamichi Kogure, Hiroshi Sekiyama, Yoshitatsu Yamada

Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan

6. The conversion of hydrocodone to hydromorphone and nonhydrocodone comparison in subjects with chronic pain

Neenah Barkat, Rabia Ayaye, Joseph Mar, Brooke Best, Amanda Pescor

University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, *Astra A. Howell Palliative Care Service, San Diego, CA, USA, *UCSD Department of Pediatrics, Rady Children’s Hospital-San Diego, San Diego, CA, USA, *Millennium Research Institute, San Diego, California, USA, *University of California Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA

7. Dose-proportionality, relative bioavailability, and effects of food on bioavailability of an immediate-release oxycodone HCl tablet designed to discourage tampering

R. Amy Puenpatom

Pfizer Inc., Cary, NC, USA, *Worldwide Clinical Trials Drug Development Solutions, Austin, TX, USA, *Worldwide Clinical Trials Drug Development Solutions, San Antonio, TX, USA

8. Daily average consumption of oxycodone CR and oxymorphone ER before and after the introduction of reformulated oxycodone CR

P. Amy Puenpatom, Kent Summery, Robert Garvin, Larry Mair, Sheryl L. Steinfeldt, Rami Ben-Joseph

Endo Pharmaceuticals Inc., Chadds Ford, PA, USA, *Ohio State University, College of Pharmacy, Columbus, OH, USA

9. A viable methodology for assessing the onset of treatment for low back pain

Jeroerd Petropolsky, Lee Bark, Guninder Banu, Geraldine Doyle, Shije Chen, Lisa Baird, Paul Despardin, Jill Starke

Loma Linda University, Department of Physical Therapy, Loma Linda, CA, USA, *Pfizer Consumer Healthcare, Madison, NJ, USA

10. A posthoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) vs oxycodone controlled release (CR) in patients ≥75 years of age

David Bandi, Jim Xiang, Mils Etozopolous, Bruce Markovitz


11. A posthoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies

David Bandi, Jim Xiang, Mils Etozopolous, Bruce Markovitz


12. Treatment of painful diabetic peripheral neuropathy in the nursing home: prevalence of the disease and conformance with a new evidence-based guideline

Frank Brave

Mid Atlantic PharmaTech Consultants, LLC, Ventnor, New Jersey, USA

13. Initial findings on abuse rates and routes of administration following introduction of reformulated OxyContin® in a sentinel surveillance system of patients in substance use treatment

Theresa Cassidy, Paul Caplan, Ryan Black, Howard Chilcoat, Simon Budman, Stephen Butler

Inflexxion, Inc., Newton, MA, USA, *Purdue Pharma L.P., Stamford, CT, USA

14. Sphygmomanometry-evoked allodynia for the identification of fibromyalgia patients

Arth Chandram, Cheryl Coor, Susan Mortier, Lori McLaud, Theresa Gilgair, Lesley Arnold

Pfizer Inc., New York, NY, USA, *RTI Health Solutions, Ann Arbor, MI, USA, *University of Cincinnati College of Medicine, Cincinnati, OH, USA

15. An aid to guide primary care physicians in the differential diagnosis of fibromyalgia

Lesley Arnold, Arth Chandram, Susan Mortier

University of Cincinnati College of Medicine, Cincinnati, OH, USA, *Pfizer Inc., New York, NY, USA, *RTI Health Solutions, Ann Arbor, MI, USA
16. Evaluation of safety and efficacy of LEVADEX® (MAP00004) in treating acute menstrual migraine
Corina P. Schneberger, Shashidhar H. Korli, Syliva M. Lucaciu, Scott W. Boland, Min Wang, Bin Hu, Ian L. Brandt, Susy Chen
Headache Care Center, Primary Care Network, Springfield, MO, USA, MAP Pharmaceuticals, Inc., Mountain View, CA, USA, University of Washington Medical Center, Seattle, WA, USA, Nashville Neuroscience Group, PC, Nashville, TN, USA

17. A long-term open-label study assessing the safety and tolerability of LEVADEX® orally inhaled dihydroergotamine in adult migraineurs
Don Kellerman, Jean Chang, Shashidhar Korli, Susy Chen
MAP Pharmaceuticals, Inc., Mountain View, CA, USA

18. Pain Education School: findings from year one of an "informational healing" program
David Caso, Erica Hugo, Ronald Albrecht
Anesthesiology Service/Pain Clinic, Jesse Brown VA Medical Center, Chicago, IL, USA

19. An "informational" healing program: introduction to the Pain Education School program at Jesse Brown VA Medical Center
David Caso, Erica Hugo, Ronald Albrecht
Anesthesiology Service/Pain Clinic, Jesse Brown VA Medical Center, Chicago, IL, USA

20. The medical borderline: personality characteristics that promote increased risk of opioid misuse
Garalyn Datz, Melissa Bonneta, Tom Merken, Todd Sitzmann
Fenestra General Hospital, Hattiesburg, MS, USA, University of Southern Mississippi, Hattiesburg, MS, USA, Advanced Pain Therapy, PLLC, Hattiesburg, MS, USA

21. Test-Retest reliability of clinical sensory testing for sensorimotor polyneuropathy
Joseph O. DiDuro, Thomas J. Burke
Neuropathy Treatment Centers of America, Phoenix, AZ, USA

22. A prospective study of changes in pain numeric rating scale with physiotherapy treatment for neuropathic pain
Joseph O. DiDuro, Thomas Burke
Neuropathy Treatment Centers of America, Phoenix, AZ, USA

23. A randomized, double-blind, placebo-controlled discontinuation study of milnacipran for the treatment of fibromyalgia in patients receiving long-term milnacipran treatment
Philip Mease, Yimin Ma, Arlene Baldacchi, Robert H. Patmen, Joel M. Tsogar, Ian D Souza
Seattle Rheumatology Associates and Swedish Medical Center, Seattle, Washington, USA, Forest Research Institute, Jersey City, New Jersey, USA

24. A 3-year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia
Lesley Arnold, Allen Spear, Arlene Baldacchi, Yong Wang, Ian D Souza
University of Cincinnati College of Medicine, Cincinnati, USA, Forest Research Institute, Jersey City, USA

25. Assessing concomitant use of oxycodone formulations with known strong cytochrome P450 (CYP) 2D6 inhibitors in patients with chronic pain
Natalie M. Elder, Roba S. Ayaye, Joseph D. Mars, Bhuva M. Bint, Armade A. Puse
University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA, Doris A. Howell Palliative Care Service, La Jolla, CA, USA, University of California San Diego Department of Pediatrics, Rady’s Children’s Hospital, San Diego, CA, USA, University of California San Diego Department of Pathology, La Jolla, CA, USA

26. Perceiving pain in oneself and others: the influence of perspective and priming
Samantha R. Fashler, Kate N. McCrystal, Daniel Jones, Judith Verlaeze, Kenneth D. Craig
University of British Columbia, Vancouver, BC, Canada, University of Toronto, Toronto, ON, Canada

27. Perceiving pain in sports injuries: behavioral, contextual and cognitive factors
Kate N. McCrystal, Samantha R. Fashler, Judith Verlaeze, Kenneth D. Craig
University of British Columbia, Vancouver, British Columbia, Canada, University of Toronto, Toronto, Ontario, Canada

28. Prescription adherence among chronic pain patients: does monitoring according to the SAFE USE treatment monitoring program clinical guidelines for chronic opioid therapy improve patient adherence? a
B. Baker Fore
1 The Wellness Center, Ardmere, OK, USA, 2Mercy Memorial Hospital, Ardmere, OK, USA

29. Participation in a regional hydromorphone safety initiative
Marie Fox, Marcia Dull Shaw, Robert Guinnini
Abingdon Memorial Hospital, Abingdon, PA, USA

30. When is more too much? A case of opioid induced neurotoxicity
Marie Fox, Asap Patel
Abingdon Memorial Hospital, Abingdon, PA, USA

31. Safety of diclofenac sodium topical solution compared with oral diclofenac for osteoarthritis of the knee in patients aged ≥65 years: pooled analysis from two controlled trials
Sanford Roth, Philip Faller
1 Arizona State University, Phoenix, AZ, USA, 2Covidian, Hazzledow, MO, USA

32. Efficacy of diclofenac sodium topical solution compared with oral diclofenac: a by-question analysis of 3 WOMAC dimensions in patients with osteoarthritis of the knee
Sanford Roth, Philip Faller
1 Arizona State University, Phoenix, AZ, USA, 2Covidian, Hazzledow, MO, USA

33. Assessment of chronic pain, impact on quality of life, and medication use utilizing a patient questionnaire
Dean Gianakos, Beth Vanderheyden, Scott E. Olson, Maureen L. Blattner, Peggy Lotkowitch, Therese Cardosi
Pfizer, Inc., New York, NY, USA, Arthritis Foundation, West Allis, Wisconsin, Upper Midwest Region, USA, Arthritis Foundation, Iselin, NJ, Northeast Region, USA, Arthritis Foundation, Kansas, IL, USA
34. Bioavailability of crush-resistant oxymorphone extended-release 40 mg with ethanol under fasted conditions
William Fiske, Janet Jobes, Qinfang Xiang, Errrol Gould, Irma Benedek
Endo Pharmaceuticals Inc., Chadds Ford, PA, USA

35. Bioequivalence of crush-resistant oxymorphone extended release 40 mg and oxymorphone extended release 40 mg under fed conditions
Irma Benedek, Janet Jobes, Qinfang Xiang, Errrol Gould, William Fiske
Endo Pharmaceuticals Inc., Chadds Ford, PA, USA

36. Effectiveness and safety of lidocaine 5% patch as add-on treatment in patients with alldynia caused by postherpetic neuralgia, diabetic neuropathy, or low back pain
Srinivas Nalamachu, Matthew S. Wiemann, Errrol M. Gould
International Clinical Research Institute, Overland Park, KS, USA, Endo Pharmaceuticals Inc., Chadds Ford, PA, USA

37. Efficacy, safety, and tolerability of HZT-501, including users of low-dose aspirin (LDA), a single-tablet combination of ibuprofen-famotidine: results of two phase 3 trials
Michael Weinblatt, Mark Genovese, Alvin Kritz, Al Bello, Amy Grabin, Michael Schiff
Harvard Medical School Division of Rheumatology, Boston, MA, USA; Stanford University, Stanford, CA, USA; Altobon Center for Clinical Research, Altobon, PA, USA; Illinois Bone and Joint Institute, Glenview, IL, USA; Horizon Pharma USA Inc, Northbrook, IL, USA, University of Colorado, Denver, CO, USA

38. Long-term safety of an NSAID with built-in gastroprotection for treatment of pain and inflammation related to OA and RA: comparative results from blinded and open-label one-year safety trials of a single-tablet combination of ibuprofen-famotidine
Jay Goldstein, Sharad Lakhanyali, Stanley Cohen, Al Bello, Amy Mathin, Alvin Kritz
University of Illinois, Chicago, IL, USA, Metropolis Clinical Research Center, Dallas, TX, USA, Illinois Bone and Joint Institute, Morton Grove, IL, USA, Horizon Pharma USA Inc, Northbrook, IL, USA, Altobon Center for Clinical Research, Altobon, PA, USA

39. An innovative Risk Evaluation and Mitigation Strategy (REMS) for Abstral, a transmucosal immediate-release fentanyl (TIRF) product
Greg Gould, Anthony G. Dlouhy, Bridget D'Mahony, Kristina Crockett, Julian Howrylak
ProStrakan Inc., Inc., Bedminster, NJ, USA, ProStrakan Group Plc, Badsworth TDI 1QH, UK, RelayHealth Pharmacy, Atlanta, Georgia, USA

40. Inter- and intra-subject variability of urinary norbuprenorphine to buprenorphine metabolic ratios in pain patients
Alexander Y. Guo, Rabia S. Atayero, Joseph D. Mar, Brooke M. Bert, Amadeu J. Pais
University of California, San Diego, La Jolla, CA, USA, Altobon A. Nowell Palliative Care Service, San Diego, CA, USA, UCSD Department of Pediatrics, Rady Children's Hospital, San Diego, CA, USA, Millennium Research Institute, San Diego, CA, USA, Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA

41. Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opioid-tolerant patients with chronic low back pain
Martin Hale, Srinivas Nalamachu, Anil Khan
Gold Coast Research, LLC., Weston, FL, USA, International Clinical Research Institute, Overland Park, KS, USA, Northwest Clinical Research Center, Bellevue, WA, USA

42. Perceived pain, disability, and psychometric measures in neuropathic vs nociceptive pain
Maryam Saracoglu, Joseph R. Gracisoro, Maxine M. Kurosad, R. Norman Harden
University of Chicago, Chicago, IL, USA, Northwestem University Feinberg School of Medicine, Department of Physical Medicine & Rehabilitation, Chicago, IL, USA

43. Providing optimal care to the chronic pain patient in the community pharmacy: a patient survey
Erron Sawick, Chris Herndon
Southern Illinois University Edwardsville, Edwardsville, IL, USA

44. Knowledge of chronic pain: an analysis of health literacy
Jake Griffin, Radhika Deyrup, Chris Herndon
Southern Illinois University Edwardsville, Edwardsville, IL, USA

45. Oral local anesthesia successfully ameliorated neuropathic pain in an upper limb, suggesting pain alleviation through neural plasticity within the central nervous system: a case report
Jin Hozumi, Masahiko Sumitani, Arito Yasui, Toshya Tomaoka, Hiroshi Sekiyama, Satoru Miyashita, Yoshitsugu Yamada
Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, Department of Rehabilitation Medicine, The University of Tokyo, The Graduate School of Medicine, Tokyo, Japan, Kobe Advanced ICT Research Center, National Institute of Information and Communications Technology, Kobe, Japan

46. Donepezil could reverse pregabalin/gabapentin-induced somnolence in patients with neuropathic pain
Koichi Sagaumi, Masahiko Sumitani, Takamichi Kogure, Kenji Azuma, Hiroshi Sekiyama, Satoru Miyashita, Yoshitsugu Yamada
Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, CREST brain function imaging team, Kobe Advanced ICT Research Center, National Institute of Information and Communications Technology, Hyogo, Japan

47. Analysis of Pain Management Team patient survey
Christine Kahley, Christine Higgins, Alisha Cain
York Hospital, York, PA, USA

49. Medication error reporting practices in hospice
Mina Kim, Mary Lynn McPherson
University of Washington Medical Center, Seattle, WA, USA, University of Maryland School of Pharmacy, Baltimore, MD, USA

50. Incidence of hydromorphone associated opioid-induced neurotoxicity
Justin Kullgren, Larry Warren Wheeler
Roseman University of Health Sciences, Henderson, NV, USA, Nathan Adelson Hospice, Las Vegas, NV, USA

51. Comparison of oral fluid and urine drug testing in a population of those with chronic pain
Sergey Letsheyu, David Masters-Moore, Charles Mikel Millennium Research Institute, San Diego, CA, USA
52. Using quantitative urine drug levels to monitor adherence to chronic opioid therapy: a comparison across two pain populations
Russell Portenoy, Harry Leider, Ariel Lindent, Kathryn Bronstein, Laura Dhingrat, Helena Knothova, Ricardo Cruciani
Beth Israel Medical Center, New York, NY, USA; Amentos, Ltd., Baltimore, MD, USA; Linden Consulting Group, LLC, Portland, OR, USA

53. Healthcare provider perspectives on managing pain in the geriatric population
Samantha O. Luik, Rabia S. Ateyey, Joseph D. Mar, Brooke M. Best, Amadeo J. Pecora
University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA; Doris A. Howell Palliative Care Service, San Diego, CA, USA; UCSD Department of Pediatrics, Rady Children’s Hospital, San Diego, CA, USA; Millennium Research Institute, San Diego, CA, USA; Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA

54. The distribution of diazepam urinary metabolites in a sample of patients with chronic pain
Samantha O. Luik, Rabia S. Ateyey, Joseph D. Mar, Brooke M. Best, Amadeo J. Pecora
University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA; Doris A. Howell Palliative Care Service, San Diego, CA, USA; UCSD Department of Pediatrics, Rady Children’s Hospital, San Diego, CA, USA; Millennium Research Institute, San Diego, CA, USA; Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA

55. A survey of ambulatory care pharmacist’s perceptions and use of state controlled substance registries
Karen Marlowe, Emily McCay
Auburn University, Auburn, AL, USA; University of South Alabama, Mobile, AL, USA

56. Update on the safety of pharmaceutical-grade dimethyl sulfoxide as a penetration enhancer for diclofenac sodium topical solution
Jeffrey Patrick, Karrie Marren
Coviden, Hazlewood, MO, USA

57. Provider adherence to an institution-wide opioid therapy policy for patients with chronic noncancer pain in the primary care setting
Michele Matteweier, Alexander Tinsor, Robert Jamison, Edgar River, Lori Teichler
Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA; Brigham and Women’s Hospital, Boston, MA, USA

58. Lifestyle Redesign for Chronic Headaches
Susan McNeil, Soma Sahai-Srivastava
University of Southern California, Los Angeles, CA, USA

59. Will the FDA’s REMS for opioids become an Emerging Solution in Pain (ESP)?
Bronwyn Bayes, Joan Meyer
MediCom Worldwide, Inc., Morrisville, PA, USA

60. Effectiveness of nonpharmacological/noninterventional CBT based treatment for chronic pain
Rick F. Meyers, Kathy Savick, Janice Veehuizen, Ed Daly, Steven-Tackett Nelson, Rebecca Ricon
Valley Pain Clinic, Salem, OR, USA; Behavioral Care Network, Salem, OR, USA; Oregon Health and Sciences University, Portland, OR, USA

Armando Miciano, Jacqueline Darhovs, Chad Cross
Nevada Rehabilitation Institute, Las Vegas, NV, USA; University of Nevada, Las Vegas, NV, USA

62. Direct medical costs of opioid management and the functional status of subjects with polytrauma history >two years and chronic noncancer pain: impact on healthcare utilization and life care planning
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA

63. Quantification of skeletal muscle mass by Bioelectric Impedance Analysis in elderly individuals with chronic nonmalignant pain and in asymptomatic individuals and its relationships among impairments in gait and balance, functional limitations, and disability
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA

64. The functional status due to Pain-Related Impairments, according to the AMA Guides Sixth Edition, and the physical performance status of subjects with a >two-year polytrauma history and with a spine impairment: a descriptive case study
Armando Miciano, Chad Cross
Nevada Rehabilitation Institute, Las Vegas, NV, USA; University of Nevada, Las Vegas, NV, USA

65. Determining the functional status, according to the AMA Guides Sixth Edition, Pain-Related Impairment, and physical performance of community-dwelling adults with osteopenia and with lower extremity pain
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA

66. Direct medical costs of pain specialist visits, the multimorbidity burden, pain-related impairment, and the physical performance on subjects with polytrauma history >two years and chronic nonmalignant pain: impact on life care planning
Armando Miciano
Nevada Rehabilitation Institute, Las Vegas, NV, USA

67. Therapeutic monitoring of benzodiazepines in the population of patients treated for pain: current limitations of inoffice immunoassays necessitate testing by mass spectrometry to assure accuracy
Rafael Miguel, Christopher Russo
Pain Medicine Program, Department of Neurology, University of South Florida, Tampa, Florida, USA
85. Concurrent quantification of itch sensation and pain in patients with postherpetic neuralgia by PainVision
Masashi Sekiyama, Kanro Hanasaki*, Takamichi Kogure, Kenji Azuma, Masahiko Sumitani, Yoshitoshi Yamada
Department of Anesthesiology, University of Tokyo, Tokyo, Japan, Department of Anesthesiology, Tokyo, Japan

86. Assessing the abuse potential of crushed EMBEDA® compared to crushed morphine sulfate-controlled-release tablets and placebo in nondependent, recreational opioid users following intranasal administration
Beatrice Setnik, Jody Cleveland, Veerairandai Goli, Naama Levy-Cooperman, Ira Smitr
Pfizer Inc., Cary, NC, USA, Kendall Early Phase, Toronto, ON, Canada

87. Self reports of prescription opioid misuse, abuse and diversion in a sample of chronic pain patients treated in primary care settings: preliminary findings
Beatrice Setnik, David Brown, Carl Roland
Pfizer Inc., Cary, NC, USA

88. A biomarker panel to assess depression in pain patients
Joseph Shrum*, George Koobs, Rosa Navarro, Brett Shrum, Katie Smith, John Bilalla
Scrpps Memorial Hospital, San Diego, CA, USA, Scripps Research Institute, La Jolla, CA, USA, Navarro Pain Control Group, Inc., San Diego, CA, USA, Ridge Diagnostics, Inc., San Diego, CA, USA, 12401 W. Shire Blvd, Los Angeles, CA, USA

89. Ischemic ulcer pain includes not only nociceptive pain but neuropathic pain components, based on a discriminant function analysis using McGill Pain Questionnaire
Takamichi Kogure, Masahiko Sumitani, Aiko Yosi, Ornabou Uematsu, Satoru Miyachi, Yoshitoshi Yamada
Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan, Department of Rehabilitation Medicine, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, Department of Anesthesiology, Osaka University, Graduate School of Medicine, Osaka, Japan, Kobe Advanced ICT Research Center, National Institute of Communications and Technology, Kobe, Japan

90. Prevalence of CYP450 drug-drug exposures among oxycodone CR patients
Joseph V. Pergolizzi, Somadha Lahitawat, Kent Summer, R Amy Pauwels, Rami Ben-Joseph, Chommy Fu

91. Comparison of ECG and Holter monitoring QTc interval measurements in patients with increased risk for QTc prolongation
Arun Sundaram, Ashish Nafissi, Paul Schweitzer, Eliza Dorrin, Peter Homan, Daniel Feldman, Russell Pontenay, Ricardo Cruceanu
Dept Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, New York, USA, Dept Neuro & Anesth, Albert Einstein College of Medicine, Bronx, New York, USA, Dept PM&R, New York University, New York, New York, USA

92. Usability of an experiential course to educate medical students in proper use of opioids in the treatment of pain
Bradley Tanner, Mary Metcalf, Susan Wilhelm
Clinical Tools, Inc, Chapel Hill, NC, USA

93. Improvement in sleep maintenance and early morning awakenings in adult and elderly patients with insomnia treated with doxepin 3 and 6 mg
Robert Taylor*, Joseph Pergolizzi, H Heith Durrance*, Brian Dorsey, Roberta Rogowski, Thomas Roth
NEMA Research Inc., Naples, FL, USA, Janssen Pharmaceuticals, San Diego, CA, USA, Henry Ford Sleep Disorders Center, Detroit, MI, USA

94. Consistency of symptom improvement in elderly adults with chronic insomnia treated with doxepin 1 mg, 3 mg, and 6 mg
Robert Taylor*, Joseph Pergolizzi, H Heith Durrance*, Roberta Rogowski, Thomas Roth
NEMA Research Inc., Naples, FL, USA, Johns Hopkins University School of Medicine, Baltimore, MD, USA, Somaxon Pharmaceuticals, San Diego, CA, USA, Henry Ford Sleep Disorders Center, Detroit, MI, USA

95. Topical corticosteroid administration by pulsed radiofrequency energy
Forest Tennant
Veract Intractable Pain Clinic, West Covina, CA, USA

96. Chorionic gonadotropin initial doses for intractable pain
Forest Tennant
Veract Intractable Pain Clinic, West Covina, CA, USA

97. Endocrine findings and serum opioid levels after 20 years of therapy
Forest Tennant
Veract Intractable Pain Clinic, West Covina, CA, USA

98. Weekly response following a single administration of Qutenza®, an 8% capsaicin patch, in patients with postherpetic neuralgia: results of integrated analyses
Lynn R. Webster, Gordon Irving, Miroslav Baskinger, Jeffrey Tobias, Geertoric F. Vanhove
LifeFree Clinical Research, Salt Lake City, UT, USA, Swedish Pain Center, Seattle, WA, USA, NeurogesX, San Mateo, CA, USA

99. Factors that may affect carisoprodol metabolism by cytochrome P450 (CYP) 2C19 in pain patients using urinary excretion data
Stephanie Ten, Rabia Atayan*, Joseph Mar*, Brooke Bree*, Amadoe Passo*
University of California, San Diego (UCSD), Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA, Ovaris A. Howell Palliative Care Service, San Diego, CA, USA, UCSD Department of Pediatrics, Rady Children’s Hospital, San Diego, CA, USA, 4 Millennium Research Institute, San Diego, CA, USA, Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA

100. A repeat-dose, steady-state pharmacokinetic evaluation of once-daily hydromorphone ER (OROS hydromorphone ER) in patients with chronic cancer or noncancer pain
Joris Vandenbosche, Ulfr Richard*, Henry Richardson*, Johnson & Johnson Pharmaceutical Research & Development, Beerse, Belgium, Janssen-Cilag, Baa, Switzerland, Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA

101. Characterization of the pharmacokinetic profile of single-dose once-daily hydromorphone ER (OROS hydromorphone ER) vs IR hydromorphone administered over 24 hours in healthy subjects
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characterization of the steady-state pharmacokinetic profile of once-daily hydromorphone ER (OROS hydromorphone ER) vs IR hydromorphone in healthy subjects</td>
<td>Ute Richard, Joris Vandenbossche, Michael Kutch, Todd Moore</td>
<td>Janssen-Cilag, Baar, Switzerland, Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Beerse, Belgium, Applied Clinical Intelligence, Bala Cynwyd, PA, USA, Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Titusville, NJ, USA</td>
</tr>
<tr>
<td>TD-1211 demonstrates peripheral selectivity and constipation-relieving effects in patients with opioid-induced constipation</td>
<td>Aaron Yarlas, Warren Weer, Manibeth Kowalski, Shao Yu Lynchr, Bradley Darr, Steven Rapar</td>
<td>QualityMetric, Inc., Lincoln, RI, USA, Purdue Pharma LP, Stamford, CT, USA</td>
</tr>
<tr>
<td>The impact of health literacy on chronic pain</td>
<td>Julie Wolfinbarger, Meredith Adams, Robert Hurley</td>
<td>University of Florida, Gainesville, Florida, USA</td>
</tr>
<tr>
<td>Butrans® (buprenorphine) transdermal system (BTDS) improves health-related quality of life in patients with moderateto-severe chronic low back pain</td>
<td>Aaron Yarlas, Warren Weer, Manibeth Kowalski, Shao Yu Lynchr, Bradley Darr, Steven Rapar</td>
<td>QualityMetric, Inc., Lincoln, RI, USA, Purdue Pharma LP, Stamford, CT, USA</td>
</tr>
<tr>
<td>Observations on the urinary metabolic profile of codeine in patients with chronic pain</td>
<td>David Yee, Radia Atayee, Joseph Mar, Brookie Baxt, Amadeo Pesce</td>
<td>University of California San Diego (UCSD), Skaggs School of Pharmacy &amp; Pharmaceutical Sciences, La Jolla, CA, USA, Doris A. Howell Palliative Care Service, San Diego, CA, USA, UCSD Department of Pediatrics, Rady Children’s Hospital, San Diego, CA, USA, Millennium Research Institute, San Diego, CA, USA, Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA</td>
</tr>
<tr>
<td>painACTION.com: Web-based support to self-manage neuropathic pain</td>
<td>Kevin Zacharoff, Jonas Bromberg, Synne Venuti, Molly Wood, Dan Surette</td>
<td>Inflexion, Inc., Newton, MA, USA</td>
</tr>
<tr>
<td>Pharmacokinetic interaction between the opioid-analgesic fentanyl and the CYP3A inhibitor ketoconazole</td>
<td>Victoria Zewenitz, Sonja Koenig, Nina Mohn, Gisela Skopp, Juergen Buhemer, Gerd Mikus</td>
<td>Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany, Institute of Legal Medicine, University of Heidelberg, Heidelberg, Germany</td>
</tr>
<tr>
<td>Observations of oxycodone coprescriptions and nonreported prescription medications in a population of those with chronic pain</td>
<td>Elizabeth Gonzales, Murray Rosenhall, Amadeo Pesce, Charles Mikel, Robert West, Cameron West, Sergey Latyshev, Perla Almazar</td>
<td>Millennium Research Institute, San Diego, USA</td>
</tr>
<tr>
<td>Variability of meperidine metabolism and excretion in patients with chronic pain</td>
<td>Kathleen Moy, Rabia Atayee, Joseph Mar, Brookie Baxt, Amadeo Pesce</td>
<td>University of California San Diego (UCSD), Skaggs School of Pharmacy &amp; Pharmaceutical Sciences, La Jolla, CA, USA, Doris A. Howell Palliative Care Service, San Diego, CA, USA, UCSD Department of Pediatrics, Rady Children’s Hospital, San Diego, CA, USA, Millennium Research Institute, San Diego, CA, USA, Department of Pathology and Laboratory Medicine, UCSD School of Medicine, La Jolla, CA, USA</td>
</tr>
</tbody>
</table>